cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas.
作者信息
Brat Daniel J, Aldape Kenneth, Colman Howard, Figrarella-Branger Dominique, Fuller Gregory N, Giannini Caterina, Holland Eric C, Jenkins Robert B, Kleinschmidt-DeMasters Bette, Komori Takashi, Kros Johan M, Louis David N, McLean Catriona, Perry Arie, Reifenberger Guido, Sarkar Chitra, Stupp Roger, van den Bent Martin J, von Deimling Andreas, Weller Michael
机构信息
Department of Pathology, Robert H. Lurie Cancer Center, Northwestern University Feinberg School of Medicine, Ward Building, 3-140, 303 E. Chicago Ave, Chicago, IL, 60611, USA.
Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
出版信息
Acta Neuropathol. 2020 Mar;139(3):603-608. doi: 10.1007/s00401-020-02127-9. Epub 2020 Jan 29.
Abstract
摘要
相似文献
1
cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas.
Acta Neuropathol. 2020 Mar;139(3):603-608. doi: 10.1007/s00401-020-02127-9. Epub 2020 Jan 29.
2
Prognostic stratification for IDH-wild-type lower-grade astrocytoma by Sanger sequencing and copy-number alteration analysis with MLPA.
Sci Rep. 2021 Jul 13;11(1):14408. doi: 10.1038/s41598-021-93937-8.
3
Targeted copy number analysis outperforms histologic grading in predicting patient survival for WHO grades II/III IDH-mutant astrocytomas.
Neuro Oncol. 2019 Jun 10;21(6):819-821. doi: 10.1093/neuonc/noz052.
4
Clinical implications of molecular analysis in diffuse glioma stratification.
Brain Tumor Pathol. 2021 Jul;38(3):210-217. doi: 10.1007/s10014-021-00409-y. Epub 2021 Jul 15.
5
Novel, improved grading system(s) for IDH-mutant astrocytic gliomas.
Acta Neuropathol. 2018 Jul;136(1):153-166. doi: 10.1007/s00401-018-1849-4. Epub 2018 Apr 23.
6
Mitotic Index Thresholds Do Not Predict Clinical Outcome for IDH-Mutant Astrocytoma.
J Neuropathol Exp Neurol. 2019 Nov 1;78(11):1002-1010. doi: 10.1093/jnen/nlz082.
7
cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant.
Acta Neuropathol. 2018 Apr;135(4):639-642. doi: 10.1007/s00401-018-1826-y. Epub 2018 Mar 1.
8
Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities.
Acta Neuropathol. 2015 Sep;130(3):407-17. doi: 10.1007/s00401-015-1454-8. Epub 2015 Jun 19.
9
IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO.
Acta Neuropathol. 2015 Jun;129(6):867-73. doi: 10.1007/s00401-015-1438-8. Epub 2015 May 12.
10
Rapid progression to glioblastoma in a subset of IDH-mutated astrocytomas: a genome-wide analysis.
J Neurooncol. 2017 May;133(1):183-192. doi: 10.1007/s11060-017-2431-y. Epub 2017 Apr 18.
引用本文的文献
1
EGFR alteration is an adverse prognostic factor in IDH-mutant astrocytoma.
Acta Neuropathol. 2025 Aug 19;150(1):20. doi: 10.1007/s00401-025-02928-w.
2
Integrated clinicopathological-radiomic-blood model for glioma survival prediction via machine learning: a multicenter cohort study.
Neurosurg Rev. 2025 Jul 12;48(1):560. doi: 10.1007/s10143-025-03719-3.
3
Dissecting the Immunological Microenvironment of Glioma Based on IDH Status: Implications for Immunotherapy.
Cells. 2025 Jul 7;14(13):1035. doi: 10.3390/cells14131035.
4
Molecular alterations in -mutant astrocytoma: A multi-institutional retrospective study.
Neurooncol Adv. 2025 Apr 28;7(1):vdaf088. doi: 10.1093/noajnl/vdaf088. eCollection 2025 Jan-Dec.
5
Cerebrospinal Fluid-Derived Genomic Alterations Tracking Glioma.
J Mol Neurosci. 2025 Jun 20;75(3):79. doi: 10.1007/s12031-025-02361-4.
6
Dissecting PTPN7-driven aggressiveness in IDH-wildtype astrocytomas: multi-omics, clinical validation, and spatial transcriptomics for prognostic insights.
Discov Oncol. 2025 May 24;16(1):914. doi: 10.1007/s12672-025-02662-5.
7
SNUH methylation classifier for CNS tumors.
Clin Epigenetics. 2025 Mar 12;17(1):47. doi: 10.1186/s13148-025-01824-0.
8
Glioblastoma multiforme: insights into pathogenesis, key signaling pathways, and therapeutic strategies.
Mol Cancer. 2025 Feb 26;24(1):58. doi: 10.1186/s12943-025-02267-0.
9
Comparative Clinical-Imaging and Histogenetic Analysis Between Astrocytoma IDH-Mutant Grade 4 and Glioblastoma IDH-Wildtype-Is There Really a Worse One?
Diagnostics (Basel). 2025 Feb 11;15(4):438. doi: 10.3390/diagnostics15040438.
10
cIMPACT-NOW update 9: Recommendations on utilization of genome-wide DNA methylation profiling for central nervous system tumor diagnostics.
Neurooncol Adv. 2025 Jan 3;7(1):vdae228. doi: 10.1093/noajnl/vdae228. eCollection 2025 Jan-Dec.
本文引用的文献
1
CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
Neuro Oncol. 2019 Dec 17;21(12):1519-1528. doi: 10.1093/neuonc/noz124.
2
IDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations.
Brain Pathol. 2020 May;30(3):541-553. doi: 10.1111/bpa.12801. Epub 2019 Dec 3.
3
Identification of subsets of -mutant glioblastomas with distinct epigenetic and copy number alterations and stratified clinical risks.
Neurooncol Adv. 2019 May-Dec;1(1):vdz015. doi: 10.1093/noajnl/vdz015. Epub 2019 Jul 17.
4
Mitotic Index Thresholds Do Not Predict Clinical Outcome for IDH-Mutant Astrocytoma.
J Neuropathol Exp Neurol. 2019 Nov 1;78(11):1002-1010. doi: 10.1093/jnen/nlz082.
5
FOCAD loss impacts microtubule assembly, G2/M progression and patient survival in astrocytic gliomas.
Acta Neuropathol. 2020 Jan;139(1):175-192. doi: 10.1007/s00401-019-02067-z. Epub 2019 Aug 31.
6
Establishing a prognostic threshold for total copy number variation within adult IDH-mutant grade II/III astrocytomas.
Acta Neuropathol Commun. 2019 Jul 26;7(1):121. doi: 10.1186/s40478-019-0778-3.
7
MTAP Loss Promotes Stemness in Glioblastoma and Confers Unique Susceptibility to Purine Starvation.
Cancer Res. 2019 Jul 1;79(13):3383-3394. doi: 10.1158/0008-5472.CAN-18-1010. Epub 2019 Apr 30.
8
Targeted copy number analysis outperforms histologic grading in predicting patient survival for WHO grades II/III IDH-mutant astrocytomas.
Neuro Oncol. 2019 Jun 10;21(6):819-821. doi: 10.1093/neuonc/noz052.
9
Integrated molecular characterization of IDH-mutant glioblastomas.
Neuropathol Appl Neurobiol. 2019 Feb;45(2):108-118. doi: 10.1111/nan.12523. Epub 2018 Nov 15.
10
cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV".
Acta Neuropathol. 2018 Nov;136(5):805-810. doi: 10.1007/s00401-018-1913-0. Epub 2018 Sep 26.
Zotero 插件